Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.Подробнее

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCL

Safety and Efficacy of Mosunetuzumab Plus Polatuzumab VedotinПодробнее

Safety and Efficacy of Mosunetuzumab Plus Polatuzumab Vedotin

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCL

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

Glofitamab and polatuzumab vedotin in DLBCL

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCLПодробнее

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL

Combination of mosunetuzumab with CHOP in DLBCLПодробнее

Combination of mosunetuzumab with CHOP in DLBCL

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy data

Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II studyПодробнее

Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II study

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCL

Updated results from EPCORE NHL-2: epcoritamab plus GemOx in patients with R/R DLBCLПодробнее

Updated results from EPCORE NHL-2: epcoritamab plus GemOx in patients with R/R DLBCL

SUNMO trial design: mosunetuzumab plus polatuzumab vedotin vs R-GemOx in R/R NHLПодробнее

SUNMO trial design: mosunetuzumab plus polatuzumab vedotin vs R-GemOx in R/R NHL

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumab

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy